Murlentamab-MMAE, an ADC, comprises an AMHR2-directed antibody and Monomethyl auristatin E (MMAE), and is utilized in the research of colorectal and ovarian cancer.
Target:
Others
T9901A-211
* VAT and and shipping costs not included. Errors and price changes excepted
